Search
for
Sort by
Research 961–990 of 1000+
- Evaluation of bioequivalence of five 0.1 mg dutasteride capsules compared to one 0.5 mg dutasteride capsule: a randomized study in healthy male volunteers
- Hirsutism
- In vitro 5α-reductase inhibition by selected Ayurvedic herbs for androgenic disorders
- Formulation Development and Investigations on Therapeutic Potential of Nanogel from Beta vulgaris L. Extract in Testosterone-Induced Alopecia
- Zinc Therapy in Dermatology: A Review
- Design, Synthesis, and Biological Characterization of Metabolically Stable Selective Androgen Receptor Modulators
- 5-α-Reductase type 2 deficiency: is there a genotype-phenotype correlation? A review
- Scientific opinion on the tolerable upper intake level for selenium
- Modeling of chronic radiation-induced cystitis in mice
- HPTLC Method Validation for simultaneous determination of Tamsulosin Hydrochloride and Finasteride in Bulk and Pharmaceutical Dosage Form
- The significance of the apelinergic system in doxorubicin-induced cardiotoxicity
- Novel anti-aging gene NM_026333 contributes to proton-induced aging via NCX1-pathway
- Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
- Fully Natural Lecithin Encapsulated Nano-Resveratrol for Anti-Cancer Therapy
- Relationships Between Hair Chemical Elements and Nutritional Status in Oldest-Old and Centenarian Populations
- Relapsing Polychondritis Following Alopecia Areata
- Disproportionality analysis comparing safety profiles of sonidegib and vismodegib based on the FAERS database
- Isotretinoin treatment upregulates the expression of p53 in the skin and sebaceous glands of patients with acne vulgaris
- Development and Skin Penetration Pathway Evaluation Using Confocal Laser Scanning Microscopy of Microemulsions for Dermal Delivery Enhancement of Finasteride
- The Multiple Consequences of Obesity
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- Case Report: Pulsed electric field treatment of metastatic liver disease demonstrating a possible abscopal response
- Editorial: Mechanisms and novel treatments of muscle wasting
- Cold Atmospheric Plasma‐Activated In Situ Hydrogel Induces Hair Regeneration Via Immune Microenvironment Remodeling
- Research progress and strategies for the biosynthesis of keratinocyte growth factor-2 (KGF-2) in <i>Arabidopsis thaliana</i>
- Dermatological care of gender‐diverse patients in Australia
- The Progress in Bioprinting and Its Potential Impact on Health-Related Quality of Life
- Uncovering the genetic architecture and evolutionary roots of androgenetic alopecia in African men
- Beliefs and counseling practices among dermatologists regarding sexual and other adverse effects of finasteride